Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Zealand Pharma

551.5

 

DKK

 

-2.48 %

Less than 1K followers

ZEAL

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
-2.48%
-23.3%
-22.92%
-23.4%
-37.04%
-21.44%
+494.29%
+186.34%
+593.71%

Zealand Pharma is a biotechnology company. Particular focus is found in the development of drugs for the treatment of diabetes and various intestinal diseases. The company has a varied product portfolio with separate brands that are sold on a global level. The largest business is in the Nordic market. Zealand Pharma was founded in 1997 and is headquartered in Söborg, Denmark.

Read more
Market cap
39.18B DKK
Turnover
48.01M DKK
Revenue
62.69M
EBIT %
-2,029.37 %
P/E
-
Dividend yield-%
-
Financial calendar
27/3
2025

General meeting '25

8/5
2025

Interim report Q1'25

14/8
2025

Interim report Q2'25

All
Press releases
ShowingAll content types
Regulatory press release21 hours ago

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Zealand Pharma
Regulatory press release3/20/2025, 4:00 PM

Zealand Pharma increases its share capital as a result of the exercise of employee warrants

Zealand Pharma
Press release3/17/2025, 7:00 AM

Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release3/12/2025, 6:00 AM

Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

Zealand Pharma
Regulatory press release2/20/2025, 12:00 PM

Zealand Pharma convenes its Annual General Meeting 2025

Zealand Pharma
Regulatory press release2/20/2025, 9:08 AM

Correction: Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma
Regulatory press release2/20/2025, 6:00 AM

Zealand Pharma Announces Financial Results for the Full Year 2024

Zealand Pharma
Press release2/13/2025, 4:00 PM

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Zealand Pharma
Press release1/7/2025, 4:00 PM

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma
Press release1/6/2025, 4:00 PM

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Zealand Pharma
Regulatory press release12/25/2024, 4:40 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release12/25/2024, 4:30 PM

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Zealand Pharma
Regulatory press release12/19/2024, 7:58 PM

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Zealand Pharma
Press release12/10/2024, 2:00 PM

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

Zealand Pharma
Press release11/13/2024, 5:00 PM

Zealand Pharma to participate in the Jefferies London Healthcare Conference

Zealand Pharma
Regulatory press release11/11/2024, 4:00 PM

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma
Regulatory press release11/7/2024, 6:00 AM

Zealand Pharma Announces Financial Results for the First Nine Months of 2024

Zealand Pharma
Regulatory press release10/8/2024, 10:45 PM

Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism

Zealand Pharma
Regulatory press release10/8/2024, 6:40 AM

Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide

Zealand Pharma
Regulatory press release9/30/2024, 3:00 PM

Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024

Zealand Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.